Accord Healthcare, Inc., a UK-based generic pharmaceutical company, announced on Tuesday that it has added Lurasidone HCL tablets to its range of generic drugs.
Accord's product is AB-rated to Sunovion Pharma's Latuda and is being offered in 20mg, 40mg, 60mg, 80mg, and 120mg doses in 30-count bottles.
The company said that Lurasidone is an oral, atypical antipsychotic, which is a first-line treatment option for the management of schizophrenia in adults and adolescents. Atypical antipsychotics have lower potential for extrapyramidal side effects. Laurasidone is claimed to rebalance dopamine and serotonin to improve thinking, mood, and behaviour.
Divya Verma, Accord Healthcare vice president, Marketing & Portfolio, said, 'By offering lurasidone, we hope to reduce the burden of costs of long-term treatment for individuals who can benefit from this medication. A generic option in mental health treatment provides more accessible healthcare to those who are in need.'
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US
Aurisco announces Yangzhou, China manufacturing site's successful FDA inspection
Teva Pharmaceuticals and Alvotech expand biosimilars partnership in the US
Sandoz to invest USD90m in Biosimilar Technical Development Center in Slovenia